Incannex Healthcare Begins Participant Screening In Its DReAMzz Phase 2 Dose Confirmation Study Evaluating IHL-42X To Treat Obstructive Sleep Apnea

Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight

Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea.

8-K filing — Incannex Healthcare Inc. (IXHL)

Filed: 2026-09-09 AccNo: 0001213900-26-098213 Size: 247 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Incannex Healthcare Announces First Patient Dosed In Phase 2 DReAMzz Dose-Optimization Study Of IHL-42X In Obstructive Sleep Apnea Across 14 U.S. Sites

Incannex Healthcare Receives Final A$5.1M R&D Tax Incentive Refund Following Approval Of Its Overseas Findings And Amendment Of Its FY25 Tax Return

Together with the previously announced A$6,039,162.43 refund, Incannex has now received more than A$11.2 million in non-dilutive capital during 2026. The receipt further enhances Incannex’s already strong cash position